Renal Cell Cancer: State of the Art in Adjuvant Therapy

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 3, 2010-11 ,pp. : 242-250

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of Survival Rates in Patients with Metastatic Renal Cell Carcinoma According to Treatment Era Including Cytokine and Targeted Therapy

By Takagi Toshio   Kondo Tsunenori   Kennoki Takafumi   Iizuka Jyunpei   Kobayashi Hirohito   Hashimoto Yasunobu   Tanabe Kazunari  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 4, 2013-04 ,pp. : 439-443

Oxford University Press

Access to resources Recommend Favorite

Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET

By Negrier S.   Jäger E.   Porta C.   McDermott D.   Moore M.   Bellmunt J.   Anderson S.   Cihon F.   Lewis J.   Escudier B.   Bukowski R.  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 899-906

Humana Press, Inc

Access to resources Recommend Favorite

Phase II trial of interleukin 2, interferon , and 5-fluorouracil in metastatic renal cell cancer - a cytokine working group study.

By Dutcher J.   Logan T.   Gordon M.   Sosman J.   Weiss G.   Margolin K.   Plasse T.   Mier J.   Lotze M.   Clark J.   Atkins M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-84

Elsevier

Access to resources Recommend Favorite

The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle

By Zipori Dov  

Cancer and Metastasis Reviews, Vol. 25, Iss. 3, 2006-09 ,pp. : 459-467

Springer Publishing Company

Access to resources Recommend Favorite